LL37 5mg 10 Vials

Description

LL-37 Antimicrobial Peptide Innate Immune Defense Research

Pharmacodynamics

The biochemical activity of LL-37 is characterized by its high net positive charge (+6) and amphipathic alpha-helical structure. Initially, the peptide electrostatically associates with negatively charged bacterial lipopolysaccharides (LPS), leading to membrane poration and lysis. This defines the first semantic triple: [LL-37 disrupts bacterial membranes]. Additionally, LL-37 serves as a ligand for the Formyl Peptide Receptor 2 (FPR2) on leukocytes, inducing chemotaxis and the recruitment of immune cells to sites of infection. This establishes the second triple: [LL-37 activates FPR2]. Furthermore, the peptide modulates Toll-like receptor (TLR) signaling to balance the pro-inflammatory and anti-inflammatory cytokine response. This forms the third triple: [LL-37 modulates TLR4 signaling]. Quantitatively, LL-37 exhibits an isoelectric point (pI) of approximately 10.6, facilitating its interaction with anionic cellular components. Unlike BPC 157, which focuses primarily on gut and musculoskeletal repair, LL-37 provides a dedicated research pathway for investigating antimicrobial defense and systemic immune modulation.

Specification Sheet

• CAS Number: 154947-66-7
• Molecular Formula: C205H340N60O53
• Molecular Weight: 4493.3 g/mol
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

Research Observations

• Enhanced Wound Healing: Users report significantly faster re-epithelialization of dermal abrasions through the stimulation of keratinocyte migration.
• Antimicrobial Support: Experimental findings suggest potent activity against various pathogens in research models, including biofilm disruption.
• Angiogenic Modulation: According to research documentation, the peptide facilitates new blood vessel formation by interacting with endothelial cells.
• Immune Homeostasis: Cross-study analysis suggests an ability to normalize immune responses in chronic inflammatory research contexts.
• Synergistic Capacity: Often researched alongside Thymosin Alpha-1 to explore comprehensive immune-restorative protocols.

Product Profile

LL-37 is the sole human representative of the cathelicidin family, a class of pleiotropic peptides that serve as primary effectors of the innate immune system. Primarily produced by neutrophils and epithelial cells, this 37-amino acid sequence is liberated from its precursor hCAP18 through proteolytic cleavage by proteinase 3. [LL-37 regulates immune signaling].
In Brief:
LL-37 represents a high-feasibility research tool for investigating the intersection of innate immunity, antimicrobial defense, and accelerated tissue repair.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.